Back to Search Start Over

Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease

Authors :
Daniel Weintraub
Chelsea Caspell‐Garcia
Tanya Simuni
Hyunkeun R. Cho
Christopher S. Coffey
Dag Aarsland
Roy N. Alcalay
Matthew J. Barrett
Lana M. Chahine
Jamie Eberling
Alberto J. Espay
Jamie Hamilton
Keith A. Hawkins
James Leverenz
Irene Litvan
Irene Richard
Liana S. Rosenthal
Andrew Siderowf
Michele York
Parkinson’s Progression Markers Initiative
Source :
Annals of Clinical and Translational Neurology, Vol 7, Iss 4, Pp 449-461 (2020)
Publication Year :
2020
Publisher :
Wiley, 2020.

Abstract

Abstract Objective To determine the evolution of numerous neuropsychiatric symptoms and cognitive abilities in Parkinson disease from disease onset. Methods Prospectively collected, longitudinal (untreated, disease onset to year 5), observational data from Parkinson's Progression Markers Initiative annual visits was used to evaluate prevalence, correlates, and treatment of 10 neuropsychiatric symptoms and cognitive impairment in Parkinson disease participants and matched healthy controls. Results Of 423 Parkinson disease participants evaluated at baseline, 315 (74.5%) were assessed at year 5. Eight neuropsychiatric symptoms studied increased in absolute prevalence by 6.2–20.9% at year 5 relative to baseline, and cognitive impairment increased by 2.7–6.2%. In comparison, the frequency of neuropsychiatric symptoms in healthy controls remained stable or declined over time. Antidepressant and anxiolytic/hypnotic use in Parkinson disease were common at baseline and increased over time (18% to 27% for the former; 13% to 24% for the latter); antipsychotic and cognitive‐enhancing medication use was uncommon throughout (2% and 5% of patients at year 5); and potentially harmful anticholinergic medication use was common and increased over time. At year 5 the cross‐sectional prevalence for having three or more neuropsychiatric disorders/cognitive impairment was 56% for Parkinson disease participants versus 13% for healthy controls, and by then seven of the examined disorders had either occurred or been treated at some time point in the majority of Parkinson disease patients. Principal component analysis suggested an affective disorder subtype only. Interpretation Neuropsychiatric features in Parkinson disease are common from the onset, increase over time, are frequently comorbid, and fluctuate in severity.

Details

Language :
English
ISSN :
23289503
Volume :
7
Issue :
4
Database :
Directory of Open Access Journals
Journal :
Annals of Clinical and Translational Neurology
Publication Type :
Academic Journal
Accession number :
edsdoj.1733fdc8d0954e2d9d18b60b48a839a0
Document Type :
article
Full Text :
https://doi.org/10.1002/acn3.51022